

# Ruxolitinib in treatment-naive or corticosteroid-refractory pediatric patients with chronic graft-versus-host disease: final analysis of the phase II REACH5 trial

## Authors

---

Franco Locatelli,<sup>1</sup> Bulent Antmen,<sup>2</sup> Hyoung Jin Kang,<sup>3</sup> Katsuyoshi Koh,<sup>4</sup> Yoshiyuki Takahashi,<sup>5</sup> Alphan Kupesziz,<sup>6</sup> Maria Gabriela A. Dias Matos,<sup>7</sup> Yogi Chopra,<sup>8</sup> Sunil Bhat,<sup>9</sup> Ho Joon Im,<sup>10</sup> Tayfun Güngör,<sup>11</sup> Meng-Yao Lu,<sup>12</sup> Tommaso Stefanelli,<sup>13</sup> Severine Peyrard,<sup>14</sup> Yvonne Smith,<sup>15</sup> Karen Sinclair<sup>13</sup> and Cristina Diaz-de-Heredia<sup>16</sup>

<sup>1</sup>Department of Pediatric Hematology/Oncology and Cell and Gene Therapy, IRCCS Bambino Gesù Children's Hospital, Catholic University of the Sacred Heart, Rome, Italy; <sup>2</sup>Division of Pediatric Hematology and Oncology and Stem Cell Transplantation, Department of Pediatrics, Acıbadem Adana Hospital, Adana, Türkiye; <sup>3</sup>Department of Pediatrics, Seoul National University College of Medicine, Seoul National University Cancer Research Institute, Seoul National University Children's Hospital, Seoul, South Korea; <sup>4</sup>Department of Hematology/Oncology, Saitama Children's Medical Center, Saitama, Japan; <sup>5</sup>Department of Pediatrics, Nagoya University Graduate School of Medicine, Nagoya, Japan; <sup>6</sup>Pediatric Hematology Oncology, Akdeniz University School of Medicine, Antalya, Türkiye; <sup>7</sup>GRAACC, São Paulo, Brazil; <sup>8</sup>Division of Hematology/Oncology, The Hospital for Sick Children, The University of Toronto, Toronto, Ontario, Canada; <sup>9</sup>Mazumdar Shaw Medical Center, Narayana Health City, Bangalore, India; <sup>10</sup>Division of

Pediatric Hematology/Oncology, Department of Pediatrics, Asan Medical Center Children's Hospital, University of Ulsan College of Medicine, Seoul, South Korea; <sup>11</sup>Department of Hematology/Oncology/Immunology, Gene Therapy, and Stem Cell Transplantation, University Children's Hospital Zürich, Eleonore Foundation & Children's Research Center, Zurich, Switzerland; <sup>12</sup>Department of Pediatrics, National Taiwan University Hospital, Taipei, Taiwan; <sup>13</sup>Novartis Pharma AG, Basel, Switzerland; <sup>14</sup>Novartis Pharma S.A.S, Paris, France; <sup>15</sup>Novartis Ireland Limited, Dublin, Ireland and <sup>16</sup>Division of Pediatric Hematology and Oncology and Stem Cell Transplantation, Hospital Universitari Vall d'Hebron, Vall d'Hebron Institut de Recerca, Barcelona, Spain

Correspondence:

F. LOCATELLI - franco.locatelli@opbg.net

<https://doi.org/10.3324/haematol.2025.300144>

Received: October 31, 2025.

Accepted: January 27, 2026.

Early view: February 19, 2026.

Published under a CC BY license 

**Ruxolitinib in treatment-naive or corticosteroid-refractory pediatric patients with chronic graft-versus-host disease: final analysis from the phase 2 REACH5 trial**

Franco Locatelli, Bulent Antmen, Hyoung Jin Kang, Katsuyoshi Koh, Yoshiyuki Takahashi,  
Alphan Kupesiz, Maria Gabriela A Dias Matos, Yogi Chopra, Sunil Bhat, Ho Joon Im,  
Tayfun Güngör, Meng-Yao Lu, Tommaso Stefanelli, Severine Peyrard,  
Yvonne Smith, Karen Sinclair, Cristina Diaz-de-Heredia

**Supplementary Table 1.** Patient disposition (full analysis set).

	≥12 to <18 years Ruxolitinib 10 mg bid N=22 n (%)	≥6 to <12 years Ruxolitinib 5 mg bid N=16 n (%)	≥2 to <6 years Ruxolitinib 4 mg/m <sup>2</sup> bid N=7 n (%)	All patients N=45 n (%)
<b>Patients treated</b>	22 (100)	16 (100)	7 (100)	45 (100)
<b>Treatment phase ongoing</b>	0	0	0	0
Completed treatment	3 (13.6)	5 (31.3)	3 (42.9)	11 (24.4)
Discontinued from treatment	19 (86.4)	11 (68.8)	4 (57.1)	34 (75.6)
<b>Reason for discontinuation</b>				
Physician decision	5 (22.7)	3 (18.8)	0	8 (17.8)
Adverse event	4 (18.2)	1 (6.3)	1 (14.3)	6 (13.3)
Lack of efficacy	4 (18.2)	1 (6.3)	1 (14.3)	6 (13.3)
Responder	3 (13.6)	2 (12.5)	0	5 (11.1)
Disease relapse	1 (4.5)	1 (6.3)	1 (14.3)	3 (6.7)
Guardian decision	1 (4.5)	1 (6.3)	1 (14.3)	3 (6.7)
Death	0	2 (12.5)	0	2 (4.4)
Graft failure	1 (4.5)	0	0	1 (2.2)
<b>Patients completed the study</b>	14 (63.6)	10 (62.5)	4 (57.1)	28 (62.2)
<b>Patients discontinued from study</b>	8 (36.4)	6 (37.5)	3 (42.9)	17 (37.8)
<b>Reason for discontinuation</b>				
Death	6 (27.3)	3 (18.8)	2 (28.6)	11 (24.4)
Patient decision	0	3 (18.8)	0	3 (6.7)
Lost to follow-up	2 (9.1)	0	0	2 (4.4)

bid, twice daily.